Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: S&P Capital IQ Quantitative Report
|
$69.00
|
|
Provider: Wright Reports
|
$472.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Biolase Technology, Inc. Raises Q1 2012 Revenue Guidance
Biolase Technology, Inc. announced that for first quarter of 2012, it expects to report revenue of approximately $12 million. This is an increase from the guidance of $11 million provided in February 2012. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $10.51 million for first quarter of 2012.
Latest Developments for BIOLASE Inc
- BIOLASE Inc Announces NewTom BIOLASE VG3 Panoramic Oral X-Ray System Receives FDA Clearance
- BIOLASE Inc Reaffirms FY 2013 Revenue Guidance
- BIOLASE Inc Receives FDA Clearance For EPIC 10S Soft Tissue Diode Laser For Broad Spectrum Of Medical Procedures
- BIOLASE Inc Issues Q1 2013 Revenue Guidance In Line With Analysts' Estimates; Issues FY 2013 Revenue Guidance Above Analysts' Estimates
Latest Key Developments in Advanced
- Hologic Inc Receives FDA Approval For New Low-dose 3D Mammography (Breast Tomosynthesis) Solution For Breast Cancer Screening
- Echo Therapeutics Inc Announces Institutional Review Board (IRB) Approval For Clinical Trial Of Symphony CGM System
- Neovasc Inc Announces Registry Data Presented At Europcr 2013 Confirms the Neovasc Reducer Improves Cardiovascular Parameters In Refractory Angina Patients
- Elekta AB's Chairman Akbar Seddigh Declines Reelection
- Share this
- Link this
- Digg this
Follow Reuters